Clinical Trial Update: Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response [Phase 1]

View source ↗

Summary

A completed Phase I trial in melanoma patients evaluating the safety and immune response of a Mouse Tyrp2 DNA vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Mouse Tyrp2 DNA (tyrosinase-related protein 2 DNA vaccine)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Melanoma | Phase 1 | Status: COMPLETED